078 Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.